BioSpace News Archive

The U.S. Food and Drug Administration continued to take action in the ongoing response to the COVID-19 pandemic

AVEO Oncology announced that it has priced its previously announced underwritten public offering of 8,500,000 shares of its common stock at a price to the public of $5.25 per share.

Actinium Pharmaceuticals, Inc. announced the pricing of its previously announced public offering of 76,923,077 shares of its common stock at a price to the public of $0.325 per share of common stock.

Nemours Children’s Health System has announced the appointment of Kara Odom Walker, MD, MPH, MSHS, to serve as Senior Vice President and Chief Population Health Officer (CPHO), effective September 1, 2020

Constellation Pharmaceuticals, Inc. announced that it has priced an underwritten public offering of 5,500,000 shares of its common stock at a public offering price of $35.00 per share, for total gross proceeds of $192.5 million, before deducting underwriting discounts and commissions and expenses payable by Constellation.

Diagnostic tests are an important tool in anticipating and meeting the continuing and evolving public health needs as we combat COVID-19.

The University of Texas MD Anderson Cancer Center and Royal Philips today announced a collaboration to provide oncologists with evidence-based therapy and clinical trial guidance through Philips’ oncology informatics solutions and MD Anderson’s Precision Oncology Decision Support (PODS) system.

Novartis, a leader in rheumatology and immuno-dermatology, announced that the US Food and Drug Administration has approved Cosentyx® for the treatment of active non-radiographic axial spondyloarthritis, confirming Cosentyx efficacy in addressing the axial spondyloarthritis disease spectrum9.

Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced that management will present at the BMO 2020 Prescriptions for Success Healthcare Conference on Tuesday, June 23, 2020 at 9:00 am ET.

Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus” or the “Company”), announced that at a special meeting held earlier today, Lantheus’ stockholders voted to approve the issuance of common stock related to the Company’s proposed merger with Progenics Pharmaceuticals, Inc. (